CD274 and non-small cell lung carcinoma: The safety of the study was similar to that previously reported.[58] Nivolumab in combination with ipilimumab was authorized by the FDA in 2020 as a first-line treatment for patients with metastatic NSCLC who had a PD-L1 ≥ 1% (Fig. 1).